Skip to content

Thomas Brenninkmeijer

Director at Goldenrod Therapeutics.

Raised on Goldenrod Therapeutics filings

$3.2M

of $6.5M offered across 1 Form D filing

Form D filings
1
Teammates
6
Last filing
Jun 3, 2026

Company

Goldenrod Therapeutics

Biotech · Houston, TX

Brain-penetrant small molecule for Friedreich's ataxia

Investors
2
Founded
2023
Still open
$3.3M

Goldenrod Therapeutics filings

  • EquityFiled Jun 3, 2026Form D
    $3.2M/ $6.5M

Works with